The FDA established the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) as part of the 21st Century Cures Act that was signed into law in December 2016. The LPAD ...

Within 6 months, 23% of patients with Mycobacterium avium complex lung disease who had received add-on amikacin liposome inhalation suspension had a culture conversion. SAN ANTONIO — Amikacin liposome ...

The U.S. Food and Drug Administration today approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium ...

We initiated a prospective trial of an azithromycin-containing regimen for the treatment of human immunodeficiency virus-negative patients with Mycobacterium avium complex (MAC) lung disease; the ...

DRESHER, PA. (WPVI) -- We need bacteria to digest food and absorb nutrients. However, when a bacteria commonly found in soil and water gets into our lungs, it can cause trouble, in the form of a MAC ...

If you have Mycobacterium avium complex (MAC) lung disease, your doctor may suggest treatment with Arikayce. It’s a prescription drug used together with other drugs to treat MAC lung disease that’s ...

Patients with nontuberculous mycobacterial pulmonary disease caused by Mycobacterium avium complex had significantly improved survival if they achieved microbiological cure at the end of treatment, ...

In early 1979, an official of an Illinois hospital reported an increase in the number of patients from whom Mycobacterium avium complex recently had been recovered. Over the preceding 3 years ...

The MarketWatch News Department was not involved in the creation of this content. The MAC lung disease market is predicted to grow in the coming years. This growth is mainly driven by the launch of ...

A phase 3 trial evaluating a nebulized clofazimine inhalation suspension (MNKD-101) for the treatment of refractory nontuberculous mycobacterial (NTM) ...